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Abstract
Introduction: Short accessory pathway (AP) effective refractory period (ERP) is one of the 
risk factors in Wolff-Parkinson-White syndrome (WPW). The purpose of study was to 
evaluate the reproducibility of APERP measurement during a same electrophysiological study 
(EPS).  
Methods: EPS consisted of 2 APERP measurements performed prospectively in 77 patients for 
a WPW in control state (CS) at a cycle length of 400 ms (n=76) and after isoproterenol (n=56).
Results: In CS, 18 patients (24 %) had the same APERP at both measurements; 41 (54.6 %) 
had differences from 10 to 40 ms, 17 (22.4 %) had differences > 40 ms. Among 45 patients 
with initial APERP > 240 ms, 7 had an APERP ≤ 240 ms at 2nd study. Among 31 patients 
with initial APERP ≤ 240 ms, 5 had an APERP > 240 ms at 2nd study. Pearson's product-
moment correlation was 0.75. After isoproterenol, 5 patients (9 %) had the same APERPs; 37 
(66 %) had differences from 10 to 40 ms and 14 had differences > 40 ms. Among 38 patients 
with initial APERP > 200 ms, 12 had an AP ERP ≤ 200 ms at 2nd study. Among 18 patients 
with initial APERP ≤ 200 ms, 10 had still APERP ≤ 200 ms at 2nd study. Pearson's product-
moment   correlation   was   0.54.                                                                  
Conclusions:  There   are   important   variations   of   APERPs   during   EPS   mainly   after 
isoproterenol infusion.   Therefore the values of APERPs should be interpreted cautiously.
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Introduction
The prevalence of a typical Wolff-Parkinson-White (WPW) pattern is estimated to be 0.1% 
[1]. Sudden cardiac death might be the first clinical manifestation of the WPW syndrome in 
previously asymptomatic individuals [2]. A recent study [3] reports a sudden cardiac death risk 
of 0.02%/patient/year. But the risk of sudden death is increased in some clinical situations. So 
it is important to detect high risk form for developing fatal arrhythmic events, in order to 
propose a curative treatment by radiofrequency ablation in a selected asymptomatic population 
[4]. The WPW syndrome is considered as representing a risk of life-threatening arrhythmic 
events when the following association is observed [5]: 1. Sustained atrial fibrillation is induced 
[6]; 2. The shortest RR interval between preexcited beats is less than or equal to 240 ms n the 
control state in adults [6] (or an anterograde effective refractory period of accessory pathway 
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(APERP) is less than or equal to 240 ms) [7, 8]  Or the shortest RR interval between preexcited 
beats is less than 200 ms or an AP ERP is less than 220 ms (or 200 ms depending on authors) 
after isoproterenol infusion [9,10]. 
Other factors are discussed such as the presence of multiple accessory pathways and the male 
gender. Therefore, the measurement of the AP ERP during an electrophysiological study is 
important. Actually AP ablation is largely indicated and a short APERP might be sufficient to 
indicate AP ablation. The aim of this study is to evaluate the reproducibility of the 
measurement of AP ERP during the same electrophysiological study.                      
Methods
Population
Seventy seven patients, 56 males (73 %) and 21 females (27 %) aged from 8 to 57 years (mean 
age 31 ± 12 years), with a ventricular preexcitation syndrome were consecutively included in 
this study; 46 patients were asymptomatic (60 %), 20 patients had palpitations (27 %), 7 
patients had history of unexplained syncope (7 %), 2 had spontaneous documented atrial 
fibrillation (3 %). Only 2 patients (3 %) had a history of life-threatening arrhythmic events 
(ventricular fibrillation or atrial fibrillation with fast ventricular conduction).                 
Accessory pathway was septal located in 51 patients (left 23, right 28). Three patients had an 
anteroseptal location (4 %); 19 patients had a left lateral accessory pathway location (25 %) 
and 4 a right lateral location (5 %).                                                                                           
Methods
This was a prospective study performed between 2004 and 2010 after informed consent. An 
electrophysiological study was performed in patients not sedated and after cessation of 
treatment. Patients were studied by transesophageal route and/or intracardiac route [11]. The 
classical protocol was as follows:
- Incremental atrial pacing was performed until the highest rate conducted 1/1 through the 
accessory pathway and/or the AV node.                                                                                         
- Programmed atrial stimulation in control state at basic cycle lengths of 400 ms was 
performed: one atrial extrastimulus was delivered after 7 paced atrial stimuli at a cycle length 
of 400 ms from 390 ms until the AP refractory pathway or the atrial effective refractory period 
with decrement of 10 msec. 
The disappearance of the pattern of preexcitation indicated when the APERP was reached. The 
longest A1A2 that fails to conduct at the atria was considered as the effective APERP. This 
protocol was reproduced again after several minutes to study the reproducibility of the measure 
of anterograde effective refractory period.                                                                                 
The method was used to induce supraventricular tachycardia. The protocol was performed 
during 80 consecutive electrophysiological studies. Three patients were excluded from this 
protocol because sustained atrial fibrillation was induced at first programmed atrial stimulation 
and flecainide injection was required to stop it. In one patient the AP did not conduct in control 
state and the measurement of APERP was made only after isoproterenol.                         
In the absence of induction of a tachycardia conducted through the accessory pathway at a rate 
higher than 250 bpm, isoproterenol (0.02 to 10 µg.min-1) was then infused to increase the sinus 
rate to at least 130 bpm and the pacing protocol was repeated. APERP was determined twice at 
a basic cycle length of 400 ms. Isoproterenol was infused in only 56 patients: 9 patients did not 
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require isoproterenol infusion because they had  an electrophysiological malignant form in 
control state with the induction of an atrial fibrillation and short cycle lengths conducted by 
AP. Two other patients remained in atrial fibrillation without signs of malignancy after second 
programmed  stimulation  in  control  state. Poorly-tolerated  orthodromic  tachycardia  was 
induced in 5 symptomatic patients during the basal study and catheter ablation was indicated 
without evaluation after isoproterenol. In 6 children, isoproterenol infusion was poorly-
tolerated and programmed atrial stimulation was not repeated.                                                 
Definitions
Conduction over the accessory atrioventricular connection was evaluated by the measurement 
of the maximal heart rate with a 1 to 1 conduction over the accessory connection and the 
shortest atrial tachycardia cycle length at which there was 1 to 1 conduction over the accessory 
connection. A short APERP was defined in the present study as less than or equal to 240 ms in 
control state (CS) and less than or equal to 200 ms after isoproterenol.                     
Statistical   analysis                                                                      
Results were presented as mean and standard deviation and compared with the paired Student t 
test. A value of p < 0.05 was considered to be significant. Correlations were performed 
between 2 determinations of AP ERP and agreement was expressed according to the Pearson's 
correlation coefficient. It was obtained by dividing the covariance of the two variables by the 
product of their standard deviations.                                                                     
Results
Reproducibility of APERP determination in control state at basic cycle lengths of 400 ms 
(Figure 1):
Figure 1:   Representation with box plot of the value's variability around the median. PRE= AP effective 
refractory   period   (APERP);   isu:   isooproterenol                                                                          
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The mean fastest cardiac rate conducted by the accessory pathway was 214±55 bpm in control 
state and the ranges were 100 and 300 bpm. The mean sinus cycle length did no differ 
significantly during both measurements (805±12 vs 819±11msec). The dispersion of the two 
measurements of APERP is represented on a graphic in Figure 2. The mean value of APERP 
at the first study was 264±52 ms. Mean value of the second measure was 265±50 ms (NS). 
However, there were important individual changes of APERP values between both studies.
Figure 2: Representation of the dispersion of the 2 different measurements of accessory pathway refractory 
periods with an atrial pacing at basic cycle lengths of 400 ms                                                             
At the first determination, APERP was more than 240 ms (mean 299±37) in 45 patients (59 
%); mean value was the same in the second study (299±37 ms); APERP became less than or 
equal to 240 ms at second measurement in 7 patients (15.5 %) and remained more than 240 ms 
in 38 patients (84.5 %). At the first APERP determination, 31 patients (41 %) had an APERP 
less than or equal to 240 ms: 24 patients had an APERP less than or equal to 240 ms at both 
studies (77 %); 7 patients had an APERP more than 240 ms at second study (22.5 %). The 
mean absolute difference between the two trials was 25.7 ms (±25.2 ms). The variations are 
reported in Table 1.
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Table 1: Mean values of variations of APERP in control state (CS) or with isoproterenol
Twenty-eight measurements (37%) were shorter in the second trial than in the first with a 
mean difference of 34±24 ms. Thirty measurements (40 %) were shorter in the first trial than 
in the second, with a mean difference of 34± 23 ms. The Pearson’s product – moment 
correlation   was   0.75.                                                                                      
Reproducibility   of  APERP   determination   after   infusion   of  isoproterenol   (Figure   1):
The mean fastest cardiac rate conducted by the accessory pathway was 265±18 bpm after 
isoproterenol infusion. The mean cycle length between 2 measurements does not differ 
significantly (475±12 mesc vs 479±14 ms). The dispersion of the two measurements with 
isoproterenol infusion was represented on a graphic in Figure 3.
Figure 3: Representation of the dispersion of the 2 different measurements of accessory pathway refractory 
periods   after   isoproterenol   infusion                                                                                    
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The mean value of the first measurement was 223±40 ms. Mean value of the second 
measurement   was   224±48   ms   (NS).   Individual   data   differed.   At   the   first   APERP 
determination, 18 APERPs (32%) were less than or equal to 200 ms; 10 measures (56%) were 
less than or equal to 200 ms and reproducible at 2 measurements; 8 APERPs were more than 
200 ms at the second determination (46%). The mean absolute difference between two trials 
was 34±25.4 ms. Among 38 patients with initial APERP more than 200 ms, 12 measures were 
less than or equal to 200 ms at the second determination (33%). The individual variations are 
reported in  Table 1.                                                                                             
For 30 patients (53.4 %) the APERP was shorter at the second measurement than at the first, 
with a mean difference of 30±18 ms. For 21 patients (37.5 %) the first measure of APERP was 
the shortest with a mean difference of 47.6 ± 28.4ms. The Pearson's product – moment 
correlation   was   0.54.                                                                                    
Reproducibility   according   to   the   route   (intracardiac   or   transoesophageal)   of 
electrophysiological   study:                                                                        
Fourteen patients underwent transesophageal study and later intracardiac study to perform the 
accessory pathway ablation. The initial mean values of APERP measured at esophageal study 
were   significantly   shorter   than   the   values   measured   at   intracardiac   study,   but   other 
measurements did not differ significantly. The mean variations were similar either in control 
state (31±29 ms and 30±27 ms) or after isoproterenol (26±16 and 24±15 ms) (Table 2).
Table 2: Data obtained in patients studied by esophageal route and then by intracardiac route
APERP1: AP effective refractory period at first measurement; APERP2: APERP at second measurement CS: 
control state; iso: isoproterenol. Data are expressed as mean ± standard deviation and ranges 
Reproducibility   according   to   the   age:                                                              
The mean age of our population was 31±12 years. In the youngest population (30 years old or 
less), representing 36 patients, the Pearson correlation coefficient was 0.675 in control state and 
0.58 after isoproterenol infusion. In the oldest population (more than 30 years old), representing 
36 patients, the Pearson correlation coefficient was 0.78 in control state and 0.46 after 
isoproterenol infusion. The subgroups according to the age of the patient were too small to 
verify   possible   relationships   between   the   age   and   the   variability   of   APERP.
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Reproducibility according to the location of accessory pathway:                            
There were no significant differences of APERP according to the location of AP: AP was left-
sided in 19 patients and the variations were 27±25 ms in control state and 25±13.5 ms after 
isoproterenol. AP was septal in 54 patients and the variations were 24±25.5 ms in control state 
and 35±27 ms after isoproterenol. AP was right lateral side in only 4 patients and variations 
(42.5±22 ms in control state and 35±21 ms after isoproterenol) can not be interpreted.
Among the 2 patients who have presented life-threatening arrhythmic events and 2 other 
patients with syncope and malignant form of preexcitation syndrome at electrophysiological 
study; all had a maximal heart rate with a 1 to 1 conduction over the accessory pathway was 
more than 240 bpm in control state during induced sustained atrial fibrillation. AF stopped 
spontaneously and the protocol was performed in these patients. Two patients had an APERP of 
250 and 260 ms at the first measurement and a short value (210 and 230 ms) at the second 
measurement.   Other   patients   had   a   short   value   (190   ms)   at   both   measurements.    
Discussion
We reported important variations of APERPs during electrophysiological study mainly after 
isoproterenol infusion. This may mean that ERP measurement with isoproterenol cannot be 
relied upon for assessing risk. The variations could be partially explained by the various 
conditions of the autonomic nervous system. The vagal and sympathetic activities constantly 
interact, and modulate the electrophysiological behaviour of the heart under different conditions 
such as postural changes, effort, and psychological activation [12,13]. A case of emergence of 
bidirectional accessory pathway conduction in adulthood reported by Nabar A [14] highlights 
the possible emergence of an AP in adult life.                                            
Fenici and al [15] studied the reproducibility of transesophageal pacing in patients with Wolff-
Parkinson-White syndrome by two transesophageal electrophysiological studies which were 
performed approximately 3 months apart. The results of this study demonstrated that changes of 
autonomic modulation could induce significant variations in the electrophysiological parameters 
that   were   commonly   used   to   define   arrhythmogenic   risk   in   WPW   patients.   But   the 
intraindividual coefficient variation was less than 10% in all patients [16]. It was clear that 
APERP, which is dependent on the autonomic tone, could vary during electrophysiological 
study, depending on the initial stress of the patient, the occurrence of a vagal reaction or the 
induction  of  a   tachycardia.                                                                                  
As showed by Castellanos et al [16], if the accessory pathway has a short effective refractory 
period, very high ventricular rates can occur after the onset of atrial fibrillation. Under these 
circumstances, atrial fibrillation can be a life-threatening arrhythmia. The incidence of atrial 
fibrillation in the Wolff-Parkinson-White syndrome is approximately 11.5% [17]. Wellens had 
compared the length of the refractory period of the accessory pathway with the ventricular 
frequency during spontaneous or electrically induced atrial fibrillation [10] and reported a good 
correlation between the 2 values.                                                                                     
The classical values of 240 ms in controls state and 200 ms after isoproterenol as cut-off for the 
evaluation of the arrhythmic risk should be discussed and the values of APERP's interpreted 
carefully in association with other data of electrophysiological study. Male gender, young age, 
sport, septal accessory pathway (AP), multiple accessory pathways, short AP refractory period, 
atrial fibrillation (AF) were reported as risk factors of sudden death in WPW syndrome 
[6,18,19]. Pappone and al considered only the induction of a re-entrant tachycardia or atrial 
fibrillation as a risk factor of arrhythmic events in asymptomatic patients. The same group 
reported recently 3 risk factors of events and sudden death, the inducibility of tachycardia, a 
short AP refractory period (less than 250 ms in adults, 240 ms in children) and the presence of 
multiple   pathways   [7,8].                                                                                    
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Limitations of the study                                                                                     
Some of our studies were performed by transesophageal route. However 14 of these patients had 
later an intracardiac study and the variations of APERPs were similar. Nanthakumar et al [20] 
have compared transesophageal route and intracardiac rout at 24 hour interval. Despite adequate 
reproducibility, transesophageal atrial stimulation was shown to fail to predict the AP-ERP by 
intracrdiac stimulation. Differences in stimulus latency was responsible, in part, for the 
disagreement.  
Three patients were excluded after induction of atrial fibrillation at the first measurement, 
requiring flecainide to stop it. We can not prove the role of autonomic nervous system because 
no changes in sinus cycle length were found in the present study. We have not studied the 
reproducibility of the ventricular rate during induced atrial fibrillation, because AF was not 
always inducible or required flecainide to stop it.                                                                         
Only 3 patients had a spontaneous malignant form. More, the ages of our population are 
heterogeneous and a difference between younger and older patients can not be excluded. The 
data are only applicable to non sedated patients. Accessory pathways were mainly septal located 
probably because the majority of our patients were asymptomatic. Similar data were noted by 
our group [11] in a larger cohort of 645 patients with a preexcitation syndrome. At least, our 
statistical analysis can be debatable.                                                                         
Conclusion
In   conclusion   this   prospective   study   reports   important   variations   of   APERP’s   during 
electrophysiological   study   mainly   after   isoproterenol   infusion.   The   study   highlights   the 
limitation of measurement of ERP as a predictor of the future risk.  The APERP in patients with 
WPW   should   be   interpreted   with   carefulness   in   association   with   other   data   of 
electrophysiological study. We suggest repeating the measurement in patients complaining of 
palpitations or syncope to avoid missing short values of APERP.                               
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